Bayer's sale of its animal health unit is attracting interest from a wide variety of players, including private equity firms and even rivals, a new report reveals.
As Bayer completed the gigantic Monsanto crop science buyout in summer 2018, it started a large overhaul that will cut its animal health business, some consumer health brands and 10% of its workforce.
